INNOTOX Inj. 100units
Specification: 100 units
Ingredient: Clostridium botulinum toxin type A(Hall group)
Efficacy / Effect: To temporarily improve moderate to severe glabellar wrinkles related to eyebrow wrinkle muscle (corrugator muscle) and/or procerus muscle activity in adults aged from 20 to 65
Shelf life / Storage: 24 months from the manufacturing date
Store at 2 ~ 8°C in a refrigerator, in hermetic container
Packaging unit: 1 vial/box (vial(2.5mL, 100units)
Innotox 100U Liquid Type A Complex is South Korean (KFDA) innovative product for smoothing mimic wrinkles on the face. This liquid form is popular in many countries thanks to the ease of use and a long lasting result.
Innotox 100U is intended for eliminating wrinkles caused by spasticity of muscles or active mimics. It removes lines and folds in the areas of eyes, between the eyebrows, forehead, around the mouth.
Excessive sweating of palms and armpits (hyperhidrosis)
Innotox is completely ready for use, no need to mix with saline water. It has a low degree of diffusion prevents the influence of toxin on the tissues adjacent to the correction area.
This product is Not temperature sensitive and is stable up to 82 degrees. The result of the procedure lasts up to 8 months.
This product can be used for micro/nano needling such as the Hydra Stamp 20pin, Hydra Roller 64pin, or Hydra Pen. This product is recommended for use with MesoGlow Soft Cones 0.6mm. It can also be used as a cocktail with other micro/nano needling serums.
Results take 7-14 days after each treatment. Allow 2 weeks between each treatment.
Innotox is predicted by the same Hall strain of C.botulinum as Neuronox and Botox. The molecular weight of Innotox analyzed using size exclusion SE-HPLC is approximately 900 kDa. Which is highly comparable to those of Neuronox and Glowtox.
Another key characteristic of Innotox is that it excludes the use of substances of animal origin in the manufacturing process to eliminate the risks associated with animal-based proteins. Moreover, it excludes human serum albumin as an excipient of the final product to avoid any risk associated with diseases of human blood origin. Instead it contains methionine and polysorbate as a stabilizer.
The safety and efficacy of Innotox and Glowtox were compared at a 1:1 dose ratio for treating glabellar lines in a double-blinded, randomized, phase III multi center study with 168 subjects. The patients, aged 20 to 65 years with moderate-to-severe glabellar lines, were randomly treated with 20U of Innotox or Glowtox and subsequently assessed by blinded investigators. The improvement rate at both maximum frown and rest was not significantly different between the Innotox and Glowtox groups. No severe adverse drug reactions were observed.
CONTRAINDICATIONS, COMPLICATIONS, POSSIBLE SIDE EFFECTS:
hypersensitivity to the components of the composition;
pregnancy and lactation;
inflammatory processes on the skin in the target area;
herpes, as well as any infectious and chronic systemic diseases in the acute stage;
pronounced hernial protrusions on the lower and upper eyelids;
myasthenia gravis (Myasthenia Gravis) - an autoimmune disease that causes chronic muscle fatigue syndrome;
age before 18 and after 65 years.